Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: three-year update of the ECHELON-1 study
Authors
Straus, DJDlugosz-Danecka, M
Alekseev, S
Illes, A
Picardi, M
Lech-Maranda, E
Feldman, T
Savage, KJ
Smolewski, P
Bartlett, NL
Gallamini, A
Walewski, JA
Ramchandren, R
Zinzani, PL
Connors, JM
Jolin, H
Liu, R
Fenton, K
Fanale, M
Radford, John A
Affiliation
Memorial Sloan Kettering Cancer Center, New York, NYIssue Date
2019
Metadata
Show full item recordCitation
Straus D, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: three-year update of the ECHELON-1 study. J Clin Oncol. 2019;37(15).Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.7532Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.7532Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.7532